Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5T7P8
UPID:
SYT6_HUMAN
Alternative names:
Synaptotagmin VI
Alternative UPACC:
Q5T7P8; B1AMB8; B3KPK1
Background:
Synaptotagmin-6, also known as Synaptotagmin VI, plays a crucial role in the Ca(2+)-dependent exocytosis of secretory vesicles. It functions through Ca(2+) and phospholipid binding to the C2 domain, potentially serving as Ca(2+) sensors in vesicular trafficking and exocytosis. This protein is also implicated in mediating Ca(2+)-regulated exocytosis during the acrosomal reaction in sperm.
Therapeutic significance:
Understanding the role of Synaptotagmin-6 could open doors to potential therapeutic strategies.